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Abstract
We have previously reported the inhibition of bacterial topoisomerase I activity by a fluoroquinophenoxazine compound (FP-11g) with a 6-bipiperidinyl lipophilic side chain that exhibited promising antituberculosis activity (MIC = 2.5 μM against Mycobacterium tuberculosis,
SI = 9.8). Here, we found that the compound is bactericidal towards Mycobacterium smegmatis, resulting in greater than 5 Log10 reduction in colony-forming units [cfu]/mL following a
10 h incubation at 1.25 μM (4X MIC) concentration. Growth inhibition (MIC = 50 μM) and
reduction in cfu could also be observed against a clinical isolate of Mycobacterium abscessus. Stepwise isolation of resistant mutants of M. smegmatis was conducted to explore the
mechanism of resistance. Mutations in the resistant isolates were identified by direct comparison of whole-genome sequencing data from mutant and wild-type isolates. These
include mutations in genes likely to affect the entry and retention of the compound. FP-11g
inhibits Mtb topoisomerase I and Mtb gyrase with IC50 of 0.24 and 27 μM, respectively. Biophysical analysis showed that FP-11g binds DNA as an intercalator but the IC50 for inhibition
of Mtb topoisomerase I activity is >10 fold lower than the compound concentrations required
for producing negatively supercoiled DNA during ligation of nicked circular DNA. Thus, the
DNA-binding property of FP-11g may contribute to its antimycobacterial mechanism, but
that alone cannot account for the observed inhibition of Mtb topoisomerase I.

Introduction
Tuberculosis (TB) is a devastating disease caused by Mycobacterium tuberculosis infection. The
World Health Organization (WHO) reported that TB is the leading cause of death worldwide
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from a single infectious agent. The 2018 Global Tuberculosis Report estimated that TB caused
~1.6 million deaths in 2017, with up to 10 million newly diagnosed TB cases annually [1]. Significantly, drug-resistant TB poses a great threat to public health. In 2017, there were 558,000
new cases of drug resistant TB, including multidrug resistant TB (MDR-TB). resistant to
rifampicin and isoniazid (two first-line anti-TB drugs) and rifampicin-resistant TB (RR-TB)
[1]. These TB patients are more likely to have poor treatment outcomes. Therefore, there is an
urgent need for potent new TB drugs with novel modes of action [2]. Resistance to current
antibiotics also makes it difficult to treat infections caused by nontuberculous mycobacteria
(NTM). It is often difficult to distinguish between M. tuberculosis and NTM as the cause of
lung infections, so there is a medical need for new antibiotics that have broad antimycobacterial activity.
DNA topoisomerases are essential enzymes for maintaining optimal DNA topology to facilitate vital functions including replication, transcription, recombination and DNA repair [3].
Topoisomerases belong to type I or type II families corresponding to cleavage of a single or
double strand of DNA being utilized for catalysis [4] with subfamilies based on sequence
homology and mechanism [5]. Every bacterium has at least one type IA topoisomerase for
overcoming topological barriers that require cutting and rejoining of a single strand of DNA
[3, 6]. Topoisomerase I catalytic activity is essential for the viability of Mycobacterium smegmatis (Msm) and M. tuberculosis (Mtb) [7, 8], because these organisms have only one type IA
topoisomerase. Mtb topoisomerase I (MtbTopI) is a validated anti-TB target; [7, 9, 10] for
identification of inhibitors that can potentially be developed into leads for new TB therapy.
We have previously shown [11] that a fluoroquinophenoxazine compound (FP-11g, shown
in Fig 1) with a 6-bipiperidinyl lipophilic side chain inhibited the catalytic activity of Escherichia coli topoisomerase I (IC50 = 0.48 μM), and showed promising antituberculosis activity
(MIC = 2.5 μM against Mtb H37Rv, SI = 9.8 for Vero cell cytotoxicity). In this study, we followed up on the antimycobacterial activity of this compound to further explore its therapeutic
potential. The interactions of this compound with MtbTopI and DNA were characterized in
biophysical assays. Mechanism of resistance to its antimycobacterial activity was studied with
M. smegmatis. This commonly used model mycobacterial organism is non-pathogenic and fast
growing, but still shares many features with pathogenic mycobacteria.

Materials and methods
Synthesis of FP-11g
FP-11g (Fig 1) was synthesized using our previously reported procedure [11]. The structure
was confirmed by 1H NMR, and high-resolution mass spectrometry (HRMS). Purity was
determined to be >99% by reverse phase C18-HPLC.

MIC (minimum inhibitory concentration) against M. smegmatis and M.
abscessus
MIC was determined with procedures based on a previously published protocol [12]. All MIC
measurements are repeated at least 3 times, with either the same exact value or range of values
reported. M. smegmatis mc2 155 (WT from ATCC) and FP-11g resistant mutants derived
from WT were cultured in 5 ml Middlebrook 7H9 broth containing 0.2% glycerol, 0.05%
Tween 80 with or without a supplement of 10% albumin, dextrose, sodium chloride (ADN) at
37˚C with shaking. Overnight (14–16 h) cultures were adjusted to an optical density (OD600)
of 0.1 and subsequently diluted 1:10 using growth media. Fifty microliters (~105 cfu) of the
diluted culture were transferred to the individual wells of a clear round-bottom 96-well plate
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Fig 1. Structure of FP-11g.
https://doi.org/10.1371/journal.pone.0207733.g001

containing 50 μl of serially diluted compounds. The 96-well plate was then incubated at 37˚C
with shaking. After 48 hours of incubation, resazurin (final concentration 0.002%) was added
to the individual wells and the fluorescence reading at 560/590 nm was taken with a BioTek
Synergy plate reader after approximately 5h of incubation at 37˚C.
A discard isolate of M. abscessus (strain number 3718) obtained from an anonymized
patient specimen during routine care at Columbia University Medical Center was used for this
study. This clinical isolate of M. abscessus was cultured in Middlebrook 7H9 ADN broth till it
reached an optical density (OD600) of 1.0. The culture was stored at -80˚C as 1 ml aliquots containing 15% glycerol. These frozen aliquots were then used as the inoculum for M. abscessus
MIC assays. Frozen stocks did not show any reduction in viable colony counts over a period of
6 months in our laboratory conditions. Each aliquot was subjected to only one freeze- thaw
cycle per MIC assay. Unused portions of each frozen stock was discarded after each assay. Frozen stocks were used to improve the consistency of the initial bacterial load in the MIC assay
and also to reduce the variations in inoculum preparation due to the slow growth pattern of
M. abscessus. Prior to conducting each MIC assay, an aliquot of frozen M. abscessus was
thawed and diluted 1:100 in Middlebrook 7H9 broth. After dilution, the bacterial cells (~105
cfu) were added to the wells of a 96-well plate containing the serially diluted compounds as
described for M. smegmatis cells and incubated at 37˚C with no shaking for 48 h. Subsequently,
resazurin (final concentration 0.005%) was added to each well and fluorescence reading at
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560/590 nm (excitation/emission) was taken after 24 h of incubation at 37˚C. MIC was determined as compound concentration that showed at least 90% reduction in fluorescence when
compared to the control (no inhibitor) wells. Ciprofloxacin and Clarithromycin were included
in the assay as positive controls. As mentioned above, on the day of each MIC assay, thawed
inoculum of M. abscessus was serially diluted and spread plated on LB agar plates to confirm
for the inoculum load of ~105 cfu/well. MIC determination for each bacteria was repeated at
least three times.

Survival assays
The bactericidal effect of FP-11g compound was evaluated in 96-well plates using a protocol
similar to the MIC assay. In brief, M. smegmatis was incubated at 37˚C with shaking in the
presence of 1X, 2X, 4X and 8X MIC of FP-11g for 6, 10, 24 and 48 hours; M. abscessus was
incubated at 37˚C without shaking in the presence of 1X and 2X MIC of FP-11g for 24, 48 and
72 hours. At each time point 20 μl from the treatment wells were serially diluted (10 fold),
spread on LB agar plates and incubated at 37˚C for 4 or 7 days for counting the viable colonies
of M. smegmatis and M. abscessus respectively. Ten microliters from the treatment wells were
also enriched in 5-ml of Middlebrook 7H9 broth if there are no viable colonies from a particular treatment-time combination on the LB agar plates. The survival percentage was calculated
by dividing the number of viable colonies at each time point by the initial viable count prior to
the treatment (time 0). Survival assays were repeated three times.

Isolation of resistant mutants
M. smegmatis mc2 155 was exposed stepwise to increasing concentrations of FP-11g to isolate
mutant strains with different levels of resistance for FP-11g by a slightly modified protocol as
described by Fujimoto-Nakamura et al [13]. Overnight culture of M. smegmatis was adjusted
to an optical density (OD600) of 0.1 and a volume of 100 μl (2x106 cfu) was spread on 7H9
ADN agar containing 2.5 μM (8X MIC) FP-11g for isolation of resistant mutants. Colonies
appearing on these plates were scored as resistant mutants only if they grew again on 7H9
ADN broth and agar plates containing 8X MIC of FP-11g. Mutation frequency was calculated
based on these resistant colonies. Only one resistant mutant was isolated at 8X MIC of FP-11g.
This resistant mutant was next exposed to 16X MIC of FP-11g in 7H9 ADN broth to further
isolate resistant colonies PGM1, PGM2 shown in Table 1. As our initial resistant mutation isolation at 8X MIC of FP-11g resulted in only one mutant, a second round of stepwise mutation
was initiated with 4X MIC to higher concentrations of FP-11g (PGM3 –PGM6 shown in
Table 1).
Table 1. FP-11g resistant mutants, resistance levels and cross-resistance to Moxifloxacin.
M.
FP-11g concentration for
smegmatis mutant isolation
Strain
X MIC (0.31 μM)

FP-11g
Fold-increase in Moxifloxacin MIC
MIC (μM)
FP-11g MIC
(μg/ml)

Fold-increase in
Moxifloxacin MIC

Streptomycin MIC
(μg/ml)

Fold-increase in
Streptomycin MIC

WT

N/A

0.31

N/A

0.08–0.16

N/A

0.25

N/A

PGM1

8X ! 16X

2.5

8X

0.16

2X

0.25

None

PGM2

8X ! 16X

5

16X

0.32

4X

0.5

2X
Decrease

PGM3

4X ! 10X

5

16X

0.32

4X

0.125

PGM4

4X ! 13X

10

32X

0.32

4X

0.25

None

PGM5

4X ! 16X

5

16X

0.32

4X

0.25

None

PGM6

4X ! 16X

5

16X

0.16

2X

0.25

None

https://doi.org/10.1371/journal.pone.0207733.t001
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Whole genome sequencing
M. smegmatis WT and mutant strains were cultured in 5 ml of Middlebrook 7H9 ADN broth
and 2 ml was spun down for genomic DNA extraction. DNA extraction was performed using
the BACTOZOLTM Bacterial DNA isolation kit (Molecular Research Center) according to
manufacturer’s instructions. DNA quality was evaluated through the UV absorbance 260/280
ratio (>1.8) and DNA quantity was measured using a fluorescence-based Qubit1 dsDNA BR
(Broad-Range) Assay Kit (Thermo Fisher). DNA concentration was adjusted to 0.2 ng/μl with
10 mM Tris-HCl pH 8.0. After concentration adjustment, all the genomic DNA samples were
quantified once again to confirm the concentration. Library was prepared with the Nextera XT
DNA Library Prep Kit, 96 Indexes (FC-131-1096). After clean-up of the libraries, random samples were selected for the Bio-analyzer analysis to verify the average size of the fragments.
Cleaned up libraries were normalized manually and pooled together. The pooled libraries were
then denatured with NaOH (final concentration 0.1 N) and the PhiX Control v3 library added.
This mix was loaded in the pre-thawed reagent cartridge associated with the MiSeq Reagent
kit v3 and sequenced using Illumina MiSeq1 Next Generation Sequencer. FASTQ files generated from the sequencing run was further analyzed in CLC genomics workbench 10 software
(QIAGEN). Sequence of M. smegmatis mc2 155 WT strain from our laboratory was used as
reference to compare all the mutant sequences and detect variations (Single Nucleotide Variations, Deletions and Insertions).

Enzyme assays
Inhibition of MtbTopI and DNA gyrase activity was evaluated with electrophoretic analysis
[10,14–16]. Each reaction contained 1 U of enzyme, defined as the minimum amount required
for complete conversion of the DNA substrate to product.
MtbTopI relaxation inhibition assay—MtbTopI was expressed in E. coli T7 Express crystal
strain (New England Biolabs) and purified as previously described [17,18]. The relaxation
activity of MtbTopI was assayed in a buffer containing 10 mM Tris-HCl, pH 8.0, 50 mM NaCl,
0.1 mg/ml gelatin, and 0.5 mM MgCl2. Serial dilutions of FP-11g dissolved in DMSO was
mixed with 10 μl of the reaction buffer containing 1 U of enzyme (defined as minimal amount
of enzyme required for complete relaxation of substrate under assay conditions) before the
addition of 9 μl of reaction buffer containing 160 ng of supercoiled pBAD/Thio plasmid DNA
purified by cesium chloride gradient as the substrate. The reactions were terminated following
an incubation of the mixtures at 37˚C for 30 min by the addition of 4 μl of stop solution (50%
glycerol, 50 mM EDTA, and 0.5% (vol/vol) bromophenol blue) and the mixtures were analyzed by agarose gel electrophoresis with TAE buffer (40 mM Tris acetate and 1 mM EDTA,
pH 8.2). The gels were stained in ethidium bromide and photographed under UV light.
DNA gyrase supercoiling inhibition assay–Mtb DNA gyrase was purchased from Inspiralis
(Norwich, UK). The supercoiling assays were carried out by mixing serial dilutions of FP-11g
in 0.5 μl DMSO with 1 U of the enzyme in reaction buffer of 50 mM HEPES pH 7.9, 100 mM
potassium glutamate, 6 mM magnesium acetate, 4 mM DTT, 1 mM ATP, 2 mM spermidine,
0.05 mg/ml BSA, followed by the addition of 300 ng of relaxed covalently closed circular DNA,
for a final reaction mixture volume of 20 μl. The samples were incubated at 37˚C for 30 min
before the reactions were terminated and analyzed by agarose gel electrophoresis.

Surface plasmon resonance
Biacore T200 SPR instrument was used to conduct all experiments. The Biacore system
employs a sensor chip that is made of a glass chip with a thin layer of gold coated on it. SPR signals correspond to the shift of the SPR angle which is sensitive to the change in the refractive
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index in the vicinity of the metal surface because of biomolecular binding and/or dissociation.
This response is reported in the resonance units (RU), with 1 RU corresponding to 0.0001
degree of change in the reflected light angle [19]. A reference flow cell (FC) in the sensor chip
has the same surface chemistry as in the active FCs but ligands are not immobilized on the reference FC so that signals corresponding to the reference FC can be subtracted from the signals
from the active FCs in order to avoid the non-specific adsorption of analytes on the chip surface. In the SPR experiments, a blank solution (without analyte in the same buffer) is also
injected and the signals produced from this blank injection are subtracted from the signals due
to actual analyte injections to avoid bulk effect.
MtbTopI was used as ligand to immobilize on a CM5 sensor chip surface in 10 mM sodium
acetate buffer at pH 5.5, using standard amine coupling chemistry, to a level of ~13400 RU.
PBS-P (20 mM phosphate buffer, pH 7.4, 2.7 mM KCl, 137 mM NaCl, 0.05% v/v surfactant
P20) was used as the immobilization running buffer. FP-11g was used as an analyte to inject
over the ligand immobilized surface in various concentrations in the presence of PBS-P buffer
supplemented with 10% DMSO. The flow rate of all analyte solutions was maintained at 50 μl/
min. One 20 s pulse of 1M NaCl solution was injected for surface regeneration. The contact
and dissociation times used were 60s and 300s, respectively. SPR sensorgrams were both reference and bulk subtracted. All experiments were conducted at 25˚C.

Measurement of visible absorbance and fluorescence emission spectra
Visible absorbance spectra of free and bound FP-11g were recorded in a Cary Bio50 UV-VIS
spectrophotometer with the following parameters: average time of 0.1 s, data interval of 1 nm,
and scan rate of 600 nm/min. Fluorescence emission spectra were measured by using a Cary
fluorescence spectrophotometer.

DNA UV melting studies
DNA UV melting curves were determined using a Cary 100 UV-Vis spectrophotometer
equipped with a thermoelectric temperature-controller. The salmon testes (ST) DNA in the
presence of different concentrations of FP-11g in 1×BPE buffer (6 mM Na2HPO4, 2 mM
NaH2PO4, and 1 mM EDTA, pH 7) was used for UV melting studies. Samples were heated at a
rate of 1˚C min-1, while continuously monitoring the absorbance at 260 nm. Primary data
were transferred to the graphic program Origin (MicroCal, Inc., Northampton, MA) for plotting and analysis.

Dialysis experiments
Dialysis assays were carried out according to the previously published procedure [20]. Briefly,
a volume of 0.3 ml of 75 μM (bp) of ST DNA was pipetted into a 0.3 ml disposable dialyzer.
The dialysis units were then placed into a beaker with 100 ml of 1×BPE buffer (6 mM
Na2HPO4, 2 mM NaH2PO4, and 1 mM EDTA, pH 7) containing 1 μM of FP-11g. The dialysis
was allowed to equilibrate with continuous stirring for 72 hours at room temperature (24˚C).
After the dialysis, the free, bound, and total concentrations of FP-11g were determined
spectrophotometrically. These values were used to determine the DNA binding constant of
FP-11g.

DNA ligation assays
DNA ligation assays were carried out in 1×DNA T4 DNA ligase buffer (50 mM Tris-HCl (pH
7.5), 10 mM MgCl2, 1 mM ATP, and 10 mM DTT) using 1,200 units of T4 DNA ligase (New
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England Biolabs) in 100 μl of solution containing the nicked plasmid pAB1 [21] in the presence of different concentrations of FP-11g. After incubation at 37˚C for 30 min, the ligation
reactions were stopped by extraction with 100 μl of phenol. The DNA samples were analyzed
by electrophoresis in a 1% agarose gel in TAE. After electrophoresis, the agarose gel was
stained with ethidium bromide and photographed using a Kodak imaging system.

Results
Growth inhibition of M. smegmatis and M. abscessus
The MIC of FP-11g for M. smegmatis mc2 155 was found to be 0.31 μM in multiple measurements. The MIC value is the same in 7H9 media with or without ADN supplement. There is
also no effect on the MIC from shaking during the incubation. For the clinical M. abscessus
isolate, the MIC was 50 μM, compared to Clarithromycin MIC of 0.7–1.56 μg/ml (1–2 μM)
and Ciprofloxacin MIC of 12.5 μg /ml (38 μM), IC50 for 50% growth inhibition of the M.
abscessus strain was estimated to be 3–6 μM.

Bactericidal activity of FP-11g
FP-11g showed strong bactericidal activity against M. smegmatis. When M. smegmatis cells
(~1x105 cells in each well in 96-well plate) were exposed to 2X MIC of FP-11g, the cell viability
was diminished by ~ 4.5 Log after 48 hours of incubation (Fig 2A). For concentrations of 4X
MIC and 8X MIC, 24 hours were sufficient to diminish cell viability by greater than 5 Log,
with no viable cells remaining at 48 hours.
Treatment of M. abscessus with 2X MIC of FP-11g resulted in >3 Log loss of cell viability
(Fig 2B). The M. abscessus strain grows slower than M. smegmatis, so treatment was extended
to 72 hours. Because of the higher MIC value for M. abscessus, FP-11g concentrations could
only be tested at up to 2X MIC in the survival assay.

Isolation and verification of resistant mutants
The mutation frequency for resistance to FP-11g at 8X (MIC) was estimated to be 5x10-7. Six
M. smegmatis strains (PGM1 –PGM6, Table 1) isolated from stepwise increase of FP-11g concentrations were verified to be resistant to the compound by determination of MIC. An
increase in the resistance to Moxifloxacin was also observed but the fold-increase in Moxifloxacin was significantly lower than the fold-increase for FP-11g MIC. Little or no increase in
resistance to Streptomycin was observed for these FP-11g mutants. Therefore each antibacterial compound was affected to different degrees by the presence of the resistance mutations
present in these isolates.
The growth rates of the six isolated mutants were compared with strain mc2 155. The
results (S1 Fig) showed that the resistance mutations resulted in a slower growth rate when
compared to WT. The morphology of the mutant colonies does not differ significantly from
mc2 155, but the mutant colonies required 7 days to reach comparable size as mc2 155 colonies. (S1 Fig).

Mutations identified in WGS
The mutations found in each of the resistant strains are listed in Table 2. Mutations in ten different genes associated with deletions, insertions or SNV (Single Nucleotide Variations) were
detected in these mutants (S1 Table). All of the resistant strains have SNV on MSMEG_0965
gene (mspA), which codes for the major porin in M. smegmatis. This porin is important for the
permeation of nutrients and antibiotics inside the cell. Previous studies showed that the
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Fig 2. Bactericidal effect of FP-11g on M. smegmatis mc2 155 and M. abscessus. (A) The bactericidal effect of FP11g on M. smegmatis were determined using 1X (0.31 μM), 2X (0.62 μM), 4X (1.25 μM) and 8X (2.5 μM) MIC at
different time points. The downward arrow indicates that no viable colonies were detected following treatment with
4X and 8X MIC at time points beyond 10 hours. (B) Survival of clinical isolate of M. abscessus following treatment with
FP-11g at 50 and 100 μM. Percent survival is calculated by the ratio of cfu from treated culture versus cfu from culture
prior to addition of FP-11g. The error bars represent the standard deviation of results of experiments repeated three
times.
https://doi.org/10.1371/journal.pone.0207733.g002

deletion of this gene in M. smegmatis resulted in a reduced permeability to drugs such as β-lactams, fluoroquinolones and chloramphenicol [22–25]. Mutation of homologs of MspA in
Mycobacterium fortuitum was shown to affect diffusion of kanamycin into the cell [26]. Defects
in msp-like porin genes also dramatically increased the resistance of Mycobacterium chelonae
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Table 2. Mutations identified in each FP-11g resistant mutant.
Strain ID
PGM1

PGM2

PGM3

PGM4
PGM5

PGM6

Region

Gene

Type

Nucleotide

Amino acid

Ref

Allele

Ref

Allele

Functional annotation in M. smegmatis

270553^270554

MSMEG_0241

INS

-

C

L

fs

MmpL11 protein. Function unknown

1039173

MSMEG_0965

SNV

T

C

L

P

Porin MspA

6498888^6498889

MSMEG_6430

INS

-

C

S

fs

Hypothetical protein. Function unknown. Integral component of membrane

270553^270554

MSMEG_0241

INS

-

C

L

fs

MmpL11 protein. Function unknown

1039173

MSMEG_0965

SNV

T

C

L

P

Porin MspA

4715711^4715712

MSMEG_4629

INS

-

T

6498888^6498889

MSMEG_6430

INS

-

C

S

fs

6498891^6498892

MSMEG_6430

INS

-

C

D

fs

Hypothetical protein. Function unknown. Integral component of membrane

6498895

MSMEG_6430

SNV

G

C

S

C

Hypothetical protein. Function unknown. Integral component of membrane

6498901

MSMEG_6430

SNV

G

T

T

K

Hypothetical protein. Function unknown. Integral component of membrane

pseudogene
Hypothetical protein. Function unknown. Integral component of membrane

1013796

MSMEG_0933

DEL

C

-

R

fs

Conserved hypothetical protein. Function unknown

1039098

MSMEG_0965

SNV

C

T

T

I

Porin MspA

2883459

MSMEG_2820

SNV

T

G

I

S

Hypothetical protein. Function unknown. Integral component of membrane

5707525

MSMEG_5623

SNV

C

A

D

Y

L-carnitine dehydratase. Function unknown

1039098

MSMEG_0965

SNV

C

T

T

I

Porin MspA

1604708

MSMEG_1513

SNV

G

C

S

C

Conserved hypothetical protein. Function unknown. oxidoreductase activity

269640^269641

MSMEG_0240

INS

-

A

M

fs

Conserved hypothetical protein. Function unknown

1039098

MSMEG_0965

SNV

C

T

T

I

Porin MspA

1604708

MSMEG_1513

SNV

G

C

S

C

Conserved hypothetical protein. Function unknown. oxidoreductase activity

5707525

MSMEG_5623

SNV

C

A

D

Y

L-carnitine dehydratase. Function unknown

1039098

MSMEG_0965

SNV

C

T

T

I

Porin MspA

3612348

MSMEG_3552

SNV

C

G

E

Q

Conserved hypothetical protein. Function unknown

5707525

MSMEG_5623

SNV

C

A

D

Y

L-carnitine dehydratase. Function unknown

6498888^6498889

MSMEG_6430

INS

-

C

S

fs

Hypothetical protein. Function unknown. Integral component of membrane

6498891^6498892

MSMEG_6430

INS

-

C

D

fs

Hypothetical protein. Function unknown. Integral component of membrane

6498895

MSMEG_6430

SNV

G

C

S

C

Hypothetical protein. Function unknown. Integral component of membrane

6498898^6498899

MSMEG_6430

INS

-

T

P

fs

Hypothetical protein. Function unknown. Integral component of membrane

6498901

MSMEG_6430

SNV

G

T

T

K

Hypothetical protein. Function unknown. Integral component of membrane

Ref: reference; SNV: single nucleotide variation; INS: insertion; DEL: deletion; fs: frame shift
https://doi.org/10.1371/journal.pone.0207733.t002

to aldehyde based disinfectants and drugs [27]. The mspA gene is present in fast-growing
mycobacteria only, and is not found in M. tuberculosis [28, 29].
The second most frequent mutation (in 3 out of 6 mutants) detected corresponds to
MSMEG_5623 and MSMEG_6430. MSMEG_5623 gene codes for an L-carnitine dehydratase
homolog of unknown function in M. smegmatis. Tuberculist (http://svitsrv8.epfl.ch/
tuberculist) and Mycobrowser (https://mycobrowser.epfl.ch/) do not show any annotated Lcarnitine dehydratase in M. tuberculosis. However, using the blast tool it was determined that
the ORF coded by MSMEG_5623 has 32% identity when aligned with the Rv3272 from M.
tuberculosis, including Asp33 (conserved amino acid) that corresponds to the amino acid
mutated in FP-11g resistant strains. Rv3272 is annotated in Tuberculist and Mycobrowser as
well as NCBI as conserved hypothetical protein with similarity to various proteins including Lcarnitine dehydratase. MSMEG_6430, with a Thr371Lys substitution mutation detected in two
isolated mutants, is classified as a membrane protein that may have diverse functions in the
cells, such as transportation of molecules through the membrane or serving as receptors for
chemical signals [30,31]. An Ile194Ser substitution mutation was also detected in
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MSMEG_2820 which encodes for an unknown integral membrane protein. The mutations in
diverse membrane proteins detected here may affect the transport of FP-11g across the
membrane.
The remainder of detected mutations occurred at lower frequencies. MSMEG_1513
(Ser43Cys substitution) codes for a hypothetical protein with no homolog in M. tuberculosis
and has been classified as an oxidoreductase. MSMEG_0241 (homolog of Rv0202c) with frame
shift mutation detected at residue 796 encodes for MmpL11 (mycobacteria membrane protein
large), a protein that belongs to a family of transporters and contribute to the cell wall biosynthesis in mycobacteria [32]. MmpL proteins family has been associated with drug resistance in
M. abscessus and M. tuberculosis [33]. Frame shift mutation was also detected in
MSMEG_0240 (homolog of Rv0201c), which does not have a known function.

Comparison of inhibition of MtbTopI versus DNA gyrase
The IC50 of FP-11g for inhibition of E. coli topoisomerase I relaxation activity has been
reported as 0.48 μM [11]. In comparison, the IC50s for inhibition of human topoisomerase I
relaxation activity and topoisomerase IIα decatenation activity were found to be both around
3.9 μM in the previous report [11]. Here we determined the IC50 for inhibition of MtbTopI
and Mtb DNA gyrase by FP-11g (Fig 3). The IC50 for MtbTopI (average ± SD) of
0.24 ± 0.04 μM (n = 3) is ~100-fold lower than the IC50 for inhibition of Mtb DNA gyrase with
average ± SD of 27 μM ± 4 μM (n = 3).

FP-11g can interact directly with MtbTopI
To detect direct enzyme-inhibitor interaction, MtbTopI was immobilized on the CM5 chip
surface and allowed to interact with FP-11g in the analyte solution. The SPR sensorgram (Fig
4) qualitatively showed that MtbTopI interacts directly with FP-11g.

FP-11g binds to DNA with intercalation
Since FP-11g has a planar tetracyclic ring scaffold (Fig 1), it may bind to DNA by intercalation.
Fig 5 shows the visible absorption spectra (Fig 5A) and fluorescence emission (Fig 5B) spectra
of free and DNA-bound FP-11g. Binding of the compound to DNA results in a red shift of the
maximum absorbance from 386 nm to 406 nm. Interestingly, upon binding to DNA, FP-11g
has a pronounced induced visible band around 330 nm with a maximum absorbance at 334
nm. Binding of FP-11g to DNA also causes a red shift to the fluorescence emission spectrum
of FP-11g (Fig 5B). The fluorescence intensity is slightly enhanced upon binding to DNA.
Table 3 summarizes the optical properties of free and DNA-bound FP-11g.
Fig 5C shows the DNA UV melting profiles in which different concentrations of FP-11g
were added to the same concentration of ST DNA. In the absence of FP-11g, the UV melting
temperature of ST DNA (Tm) was determined to be 70.8˚C. In the presence of saturated FP11g (40 μM), the DNA UV melting temperature was increased to 81.9˚C, indicating that FP11g tightly binds to ST DNA. In this study, we also carried out a dialysis binding assay in
which 75 μM (bp) ST DNA was extensively dialyzed against a large excess of 1 μM of FP-11g.
Fig 5D shows our results. After 72 hours of dialysis, the concentration of FP-11g outside the
dialysis bag was not significantly changed. In contrast, the concentration of FP-11g inside the
dialysis bag where the ST DNA was located was increased to 25 μM. The DNA binding constant of FP-11g was estimated to be 1x106 M-1 in 1XBPE.
Fig 6 shows the results of ligation of nicked circular DNA in the presence of different concentrations of FP-11g by T4 DNA ligase. Change in DNA linking number was observed at
2 μM. Concentrations of FP-11g at 5 and 10 μM drove the plasmid DNA template into (-)
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Fig 3. Comparison of inhibition of MtbTopI and DNA gyrase activities by FP-11g. (A) Inhibition of MtbTopI relaxation of negatively
supercoiled DNA by increasing concentrations of FP-11g. (B) Inhibition of Mtb DNA gyrase supercoiling of relaxed DNA requires higher
concentrations of FP-11g.
https://doi.org/10.1371/journal.pone.0207733.g003

supercoiled DNA. This result suggests that FP-11g can act as a DNA intercalator at these
higher concentrations. The DNA intercalation of FP-11g at the observed IC50s could be the
basis for the inhibition of DNA gyrase and human topoisomerases [11], but could not be the
sole basis of inhibition of bacterial topoisomerase I observed at 10-fold lower IC50s.

Discussion
In previous studies, the FP-11g compound has been proposed as an antimycobacterial agent
active against M. tuberculosis (MIC = 2.5 μM) [11]. Here we demonstrate its activity against
the pathogenic NTM M. abscessus. Compounds active against both species would be useful in
clinical settings since in some cases the symptoms and clinical manifestations of infections
caused by these two organisms are difficult to differentiate, consequently empiric treatment
effective for both organisms is required. Additionally, patients suffering from cystic fibrosis or
other immunosuppressive condition can be infected by different mycobacteria at the same
time. In fact, co-infections with M. abscessus and M. tuberculosis have been reported [34, 35].
The strong bactericidal effect of FP-11g against M. smegmatis supports investigation of this
compound and its derivatives for its potential use as a broad antimycobacterial agent. The
finding of the growth inhibitory effect of FP-11g on M. abscessus is encouraging because of the
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Fig 4. Qualitative evaluation of the binding of FP-11g with MtbTopI using SPR. SPR sensorgrams showing the direct binding of FP-11g
with the immobilized MtbTopI. FP-11g was injected at 2.5 μM (green), 5 μM (blue), and 10 μM (red) in duplicate.
https://doi.org/10.1371/journal.pone.0207733.g004

lack of response of NTM clinical strains and subspecies of M. abscessus to nearly all of the current antibiotics.
No specific mutations found in FP-11g M. smegmatis resistant mutants could be definitively
associated with the proposed mechanism of action of this compound, but all of them may play
a role in drug resistance. Expression of M. smegmatis MspA porin in M. tuberculosis promotes
not only cell growth but also antibiotic susceptibility [36]. Other studies have also demonstrated a role of MspA porin in drug resistance of M. fortuitum and M. chelonae [26, 27]. To
date, porin genes have not yet been identified in M. tuberculosis, even though some studies
suggest the presence of these structures in these organisms [29]. The mutation in MspA porin
is likely to be the first mechanism of resistance developed by M. smegmatis, and hence the
common mutation was found. Changes in the porin may interrupt the drug transportation
into the cell and support cell survival. Since this porin is present in fast growing mycobacteria,
it would be of significance in the treatment of atypical pathogenic mycobacteria including M.
abscessus studied here [37]. The mutations affecting drug uptake identified here for the FP-11g
resistant M. smegmatis may indicate a similar mechanism involved in FP-11g uptake to partly
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Fig 5. Binding of FP-11g to salmon testes DNA in 1×BPE buffer (6 mM Na2HPO4, 2 mM NaH2PO4, and 1 mM
EDTA, pH 7). (A) Visible absorption spectra of free (black line) and DNA bound (red line). (B) Fluorescence
emission spectra of free (black line) and DNA bound (red line). The fluorescence emission spectra were recorded with
λem = nm. (C) DNA UV melting of salmon testes DNA in the presence of various concentrations of FP-11g. The FP11g concentrations are 0, 2, 5, 7.5, 10, 15, 20, and 40 μM from left to right. (D) The DNA dialysis assay was performed
as described in the Methods. Visible absorption spectra of FP-11g inside the dialysis bag (red line) and outside dialysis
bag (black line).
https://doi.org/10.1371/journal.pone.0207733.g005

Table 3. Optical properties of FP-11g in the presence and absence of ST DNA in 1×BPE buffer.
FP-11g

λmax
(nm)

ε334
M-1cm-1

ε386
M-1cm-1

ε406
M-1cm-1

ΔTma
(˚C)

Relative fluorescenceb

Free

386

4,646

6,033

5,587

N/A

1.0

Bound

406

12,321

5,284

4,418

11.1

1.5

334
a

0

ΔTm = Tm-Tm where Tm and Tm0 represent the DNA UV melting temperature in the presence and absence of 40 μM of FP-11g (Fig 4C).
At λem = 550 nm with λex = 386 nm. The fluorescence intensity is relative to that of free FP-11g.

b

https://doi.org/10.1371/journal.pone.0207733.t003
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Fig 6. Products of DNA ligation in the presence of FP-11g. DNA ligation of nicked pAB1 plasmid DNA by T4 DNA
ligase in the presence of indicated concentrations of FP-11g were performed as described under Methods.
https://doi.org/10.1371/journal.pone.0207733.g006

account for the significantly higher MIC observed for M. abscessus, and may be relevant for
the resistance to current antibiotics and new antibacterial compounds for the NTM species
[38, 39].
Characterization of integral membrane proteins has been always a challenge due to the difficulty for the expression, solubility and crystallization of these proteins. Most of the information has been obtained through computational approaches, which predict the structural
conformation of a protein based on the primary sequence and classify the different types
of transmembrane proteins [40, 41]. Transmembrane proteins could be associated with
mechanisms of resistance to drugs that are not targeting them directly. Integral component of
membrane are channels through the cellular membrane that transport amino acids, lipids,
coenzymes, carbohydrates, nucleotides and other metabolites [42]. Mutations in integral
membrane proteins detected here may affect drug transportation through the membrane. Variation in channels that transport molecules through the cell wall will affect the intake of molecules including drugs and metabolites. These integral components of membrane could also be
non-characterized efflux pumps that may be extruding the drug from the organism and support the drug resistance.
In this study we detected the MmpL11 mutation in two resistant mutants. Previous studies
with M. tuberculosis strains harboring mutations in MmpL proteins showed that all of the
mutant strains retained general drug susceptibility to diverse antibacterial agents. This suggests
that MmpL proteins do not play a direct role in drug resistance [43]. Nonetheless, recent studies have shown that the extended RND permease superfamily in M. tuberculosis include both
RND multidrug efflux transporters and members of the MmpL family [44]. In M. abscessus,
MmpL has been associated with drug resistance through efflux pumps [45]. Additionally,
mutations on MmpL11 proteins has been associated with impairment of biofilm formation in
M. smegmatis. The absence of this gene has generated a reduced permeability to antimicrobial
agents [46, 47], which is evidence that this mutation may play an important role in FP-11g
resistance.
Remarkably, we did not detect mutations in the topA gene in the resistant mutant isolates.
This might be due to FP-11g acting as an unconventional catalytic inhibitor. These types of
inhibitors are described as compounds that bind to the DNA as well as to the topoisomerase
enzyme to inhibit the topoisomerase activity [48]. Mutations that affect the essential activity of
topoisomerase I could compromise cell growth to a significant extent and would less likely be
selected for resistance than the mutations detected here that can limit compound transport
into the cell. It is also possible that due to its interaction with DNA, FP-11g inhibits multiple
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DNA binding proteins in its mode of action, including DNA gyrase as observed here. Further
studies are required to identify other analogs of FP-11g that can be more selective in targeting
topoisomerase I activity in its antimycobacterial mechanism of action. This would require
enhancing the interaction of the inhibitor with the MtbTopI enzyme, and reducing the dependence of inhibition on DNA binding.

Supporting information
S1 Fig. Effect of FP-11g resistant mutations on M. smegmatis growth and colony morphology.
(PDF)
S1 Table. Summary of mutations associated with FP-11g resistance in M. smegmatis.
(PDF)
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